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Abstract 1 
Following renal transplantation patients experience on-going immunosuppressant 2 
medication to reduce the risk of graft rejection. Over the long term the side effects 3 
of immunosuppressive drugs may affect graft survival and significantly increase risks 4 
of cancers, stroke and cardiovascular disease. To reduce these risks research is 5 
underway to develop a biomarker test to identify those patients who are likely to be 6 
‘tolerant’ to their graft and therefore able to reduce immunosuppression. Biomarker 7 
tests may however incorrectly identify some patients as tolerant, thus jeopardising 8 
their graft. Following a quantitative assessment of risk preferences we undertook a 9 
qualitative study to investigate the range of influences that shaped the substantial 10 
variations found in the level of risk transplant recipients were hypothetically willing 11 
to take. In-depth interviews were carried out in the United Kingdom between May 12 
2013 and July 2014 with 24 transplant recipients all of whom had stable kidney graft 13 
function. These interviews identified a range of factors that patients take into 14 
account when making risk assessments, including familial views, trust and the 15 
ritual of ‘gift exchange’ that permeates the social space of kidney transplantation. 16 
Our data support the notion that emotion is not part of a linear process, 17 
preceding and separate to reason, but is intertwined with personal 18 
understanding and perception of risk and involves a complex interplay between 19 
different influences on decision-making.  Our data also support Lupton’s view 20 
that risk judgements are shared and collective rather than located within the 21 
individual and suggests that patient choice rather than involving a purely 22 
rational weighing of medical benefit is often based on influences that may not 23 
accord with the framework nor intention of medical professionals and medical 24 
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research.  25 
 26 
Keywords: United Kingdom; kidney transplantation; biomarker; risk; emotion; social 27 
influences; ‘gift exchange’; trust. 28 
 29 
1. Introduction 30 
Since the early 1960s sociologists have considered the health hazards associated 31 
with the introduction of innovative forms of medical treatments and therapies as 32 
constituting a veritable ‘risk epidemic’ (Schlich & Trohler 2006:2).  This  33 
‘manufactured’ form of risk, produced by innovative developments in science 34 
and technology, has little historical reference arising instead with the process of 35 
modernization and influencing the manner in which we conceptualise and 36 
manage risk (Giddens 1999). Ulrich Beck argues that in the late modern period, 37 
with the ‘fracturing of monolithic sources of knowledge and identity in 38 
contemporary Western culture’, reliance on the ‘calculability’ of risk has been 39 
increasingly challenged (1992:71). This is due to the rise of modernity having 40 
produced situations of risk for which experts do not have answers. As a 41 
consequence many opinions are expressed and the ability to ‘calculate’ risk, once 42 
based on the ‘true’ knowledge of the expert, dissolves leaving people to 43 
‘estimate’ the risk. As such the way we come to a decision now involves 44 
individual beliefs, behaviours and ‘everyday life’ and whatever evidence we find 45 
most believable (Tulloch & Lupton 2003; Wasserman & Hinote 2011). This 46 
means that decision-making is a complex process when faced with biomedical 47 
initiatives that bring both the hope of unimaginable advances yet the possibility of 48 
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often significant negative consequences such as the clinical trial of the 49 
immunomodulatory drug TGN1412 during which catastrophic systemic organ failure 50 
occurred (Goldacre 2013). Testing of these new technologies and treatments 51 
requires service users to engage with the risk of the unstable and complex 52 
framework of scientific claims. 53 
 54 
1.1 Framing the concept of risk 55 
Disciplines frame and understand the concept of risk differently. For example the life 56 
sciences and medicine apply principles, postulates and calculations to address what 57 
is perceived as the objective reality of ‘risk’ whereas psychology views risk as a 58 
behavioural and cognitive phenomenon and focuses on judging risky behaviour (Zinn 59 
2015). In contrast anthropologists see risk as a cultural phenomenon, including the 60 
way in which risk is publicised and moralised (Althaus 2005) and sociologists 61 
emphasise risk-taking as a form of social action based on experience and tacit 62 
knowledge (Zinn 2008 & 2015). These disciplines also have varying notions of the 63 
influence of emotions on decision-making in situations of risk. The psychologist 64 
Paul Slovic argues that emotion is important in guiding judgement and decision-65 
making, with people drawing on a pool of conscious or unconscious associations that 66 
are marked to varying degrees with positive or negative feelings (Slovic 2007). 67 
Emotion is thus seen from this perspective as preceding and separate from what is 68 
described as reason (Slovic & Vastfjall 2010). Although these perspectives on risk 69 
may be relevant to elements of our findings it is Deborah Lupton’s argument that 70 
‘emotion and risk interact in the process configuring each other’ that we argue most 71 
keenly reflects our findings (Lupton 2013:641).  Lupton regards risk judgements as 72 
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imbued with emotion, whether this is at the pre-conscious, unconscious or conscious 73 
level and depicts emotion and risk as inevitably configured via social and cultural 74 
processes (Lupton 2013:634). Thus although risk may be material, as in a risk to 75 
health, it is always interpreted via a social or cultural lens. Lupton describes this in 76 
terms of an ‘emotion-risk assemblage’ that both incorporates notions of affect into 77 
the concept and also identifies the ways in which the social and its cultural 78 
manifestations shape risk perceptions and decision-making (ibid:636). However, 79 
Lupton notes that the relationship between risk and emotion remains under 80 
theorised, particularly in the context of health and medicine (ibid:637). Taking up 81 
Lupton’s conjecture we therefore consider both the place of emotion and social 82 
influences on the choices made by kidney transplant patients when faced with a 83 
biomarker test. 84 
 85 
1.2 Our study 86 
Our empirical study focuses on the process of decision-making in kidney 87 
transplant patients in the context of on-going research to develop a biomarker 88 
test to identify those patients who can be considered ‘operationally tolerant’ to 89 
their graft and who will therefore not experience rejection in the absence of 90 
immunosuppressive drugs (Heidt & Wood 2012); the term biomarker being 91 
defined as ‘a characteristic that is objectively measured and evaluated as an 92 
indicator of normal biological processes, pathogenic processes, or pharmacologic 93 
responses to a therapeutic intervention’ (OECD 2011).  It is anticipated that 94 
identifying the ‘biomarker of tolerance’ will improve the present situation where 95 
immunosuppressive drugs taken to reduce the risk of kidney graft rejection may 96 
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in themselves damage the graft and also cause long-term health problems 97 
including cancers, stroke and cardiovascular disease (NHS 2015a; Howard et al 98 
2002). However, biomarker tests are not 100% accurate with the risk that 99 
patients may be erroneously identified as tolerant. In these circumstances 100 
withdrawal of immunosuppressant medication could lead to the rejection of the 101 
graft. In this situation a patient centred approach to the research requires both 102 
to weigh the medical benefits of minimizing immunosuppression against the risk 103 
of precipitating graft rejection and to identify how patients conceptualise, 104 
interpret and respond to the risk in the context of their experiences and the 105 
priorities of their life world.  106 
 107 
The paper forms part of a larger project with the initial stage employing a 108 
quantitative approach to identify the level of risk that kidney transplant patients 109 
might be willing to take in choosing biomarker led care. In percentage terms this 110 
identified hypothetical risk levels ranging from 0% to 50%. The second 111 
qualitative phase, reported here aimed to elicit the variety and interaction of 112 
influences on their risk decisions. 113 
 114 
2. Method 115 
Participants for the qualitative study were purposively selected from the initial 116 
quantitative patient sample to include differences in age, gender, type of transplant 117 
and time on dialysis. Ethical approval was obtained for the research following which 118 
a research nurse at each of the eight participating hospitals initially contacted 119 
patients to establish whether they would be willing to consider taking part in the 120 
study.  Patients who agreed were sent a letter describing the biomarker research, 121 
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making clear that the test was not 100% accurate and explaining that the purpose of 122 
the study was to identify the level of risk that patients may be willing to take.  The 123 
first author (JH) then telephoned to discuss the study, answer any questions and for 124 
patients who agreed to be involved, set a suitable date and time.  125 
 126 
Interviews took place in people’s homes, cafes or occasionally a meeting room 127 
within a Hospital Trust. Informed consent was obtained from all participants 128 
following provision of an information sheet and opportunity to ask questions.  It was 129 
also emphasised to participants that their participation was voluntary and they could 130 
withdraw at any stage. Interviews began with participants sharing the ‘story’ of their 131 
renal failure and kidney transplant(s) to elicit the context of their decision-making.  132 
The researcher (JH) then explored issues that participant’s raised. Other 133 
considerations were also probed assisted by a topic guide designed to elicit patients’ 134 
attitude to risk, including personal priorities - past, present and future - views on the 135 
biomarker test and the level of risk they would be prepared to take if the test 136 
showed they were ‘tolerant’ and could hypothetically have their 137 
immunosuppressant medication reduced. The interviews took place over 15 months 138 
and most lasted 45-60 minutes. Three interviews were carried out in the presence of 139 
a patient’s relative – wife, husband or mother – whose voices are brought into our 140 
findings. Following 24 interviews it appeared that saturation point had been reached 141 
with no new themes emerging.  142 
 143 
Analysis occurred concurrently with interviews.  Initially the taped interviews were 144 
transcribed verbatim and pseudonym(s) assigned. Preliminary coding and thematic 145 
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analysis were then undertaken and the data entered into the software package 146 
NVivo9 to benefit from the automated search and display facilities.  Each transcribed 147 
interview was then worked through manually to achieve a more complete 148 
understanding of the fluid and creative ways that themes emerge (Welsh 2002).  149 
 150 
3.  Findings 151 
The participants comprised 24 kidney transplant patients aged between 28 and 68 152 
years from diverse backgrounds (Table 1). No one characteristic appeared to 153 
separate those who would take a low risk – expressed as between 0% and 5% - or 154 
those willing to take a risk of 20% or more.   155 
 156 
In what follows we maintain ‘risk’ terminology (Jackson, Allum & Gaskell 2006:2) by 157 
using the concepts of ‘downsides’ and ‘rewards’ to consider participants perceptions 158 
of biomarker led care. We then describe the themes of ‘trust’ and familial perception 159 
that formed significant considerations although neither a downside nor reward. The 160 
figure in parenthesis following a participant’s name represents the level of risk they 161 
were hypothetically prepared to take if identified as tolerant. 162 
 163 
3.1 Downsides of the risk  164 
Fear of graft failure is known to have a major influence on the lives of kidney 165 
transplant patients (Howell et al 2012) and our participants similarly described how 166 
the maintenance and retention of their graft was an ever-present goal. It was 167 
therefore understandable that many spoke of not wishing to tamper with their 168 
medication, often using idioms to capture the sense of maintaining the “status quo”.  169 
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 170 
For example Lorna (1%), after twelve years without rejection, did not view 171 
“interfering with the situation” as an option:  172 
I just know I’ve not had any rejection ….. . And I just assume, you know, the 173 
kidney must be tolerating what I’m being given ….. . So what I say is let 174 
sleeping dogs lie! 175 
 176 
Likewise Miranda (0%) was not about to disrupt her medication considering her graft 177 
allowed her to carry on her chosen lifestyle:  178 
Well having had this brilliant kidney for eighteen years, there is nothing I 179 
would do to risk its health.  I really wouldn’t ….. no, even at the hospital, if 180 
they said, ‘We’re going to change your anti-rejection tablets now,’ I’d be very, 181 
very wary of changing them.  I think it’s got into a nice routine now, it’s 182 
comfortable, I don’t want to rock-the-boat.  And I can’t bear….., I couldn’t 183 
bear the thought of life without it.  184 
 185 
Apart from in general not wishing to ‘meddle’ with their medication, patient’s 186 
specific perceptions of the positive and negative aspects of the risk often reflected 187 
their personal circumstances and experiences. For example, Tom (25%) revealed a 188 
history of poor health commencing at age 3 with a diagnosis of leukaemia; 189 
understandably in these circumstances he focused on the medical advantages of 190 
tolerance. In contrast, Paul (0%) with two young sons and a mortgage focused on the 191 
fear of not being able to meet his “responsibilities” should rejection of his graft occur. 192 
For Jessica (2%) who suffered very few medication side effects and was pregnant the 193 
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risk of rejection was not something she would entertain, although appreciating the 194 
long-term negative side effects of immunosuppressants.  James recently married and 195 
with his career just taking off, did not wish to disturb the feelings of “control” that 196 
the transplant gave him, despite suffering bouts of diarrhoea that he knew to be 197 
medically induced.  198 
 199 
As part of the fear of graft failure many of our participants spoke of the dialysis that 200 
would ensue. Twenty participants had experienced dialysis with ten expressly 201 
identifying it as a factor in their decision. For some the thought of returning to 202 
dialysis caused considerable emotional concern with patients speaking of the regime 203 
as “life limiting”; “a remover of freedom”; ”an awful, awful experience”.   204 
 205 
For Jack (0%) having spent 25 years on dialysis the notion of taking a risk was 206 
inconceivable: “If you’ve done two or three years and had a transplant, I don’t think 207 
you appreciate the sort of possibility of doing really long-term dialysis.” As Jack 208 
explained, he and his wife Mary would only take part if the test was 100% accurate. 209 
Similarly for Alice (25%) the idea of “being strapped” to a dialysis machine felt like 210 
“the end of my life”, a “death sentence”. Alice told how in order to avoid dialysis she 211 
and her medical team took the risk of performing a pre-emptive kidney and pancreas 212 
transplant.  Jessica (2%) who was on haemodialysis also recounted dialysis in very 213 
emotional and negative terms speaking of the way the transplant had “transformed” 214 
her back to her “normal self”.  215 
 216 
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The most common form of dialysis is haemodialysis that uses an external machine to 217 
filter blood of waste products whereas peritoneal dialysis uses the inside lining of 218 
the abdomen as a filter (NHS 2015b).  Both forms of dialysis are considered to have 219 
advantages and disadvantages (Wasserfallen et al 2004). Jenny (10%) for example 220 
chose to have peritoneal dialysis but retrospectively felt this to be intrusive: 221 
Maybe it was the dialysis I chose, quite intrusive and also a little bit 222 
demoralising.  I didn’t feel whole because I constantly had a reminder  ….. you 223 
know, it’s not normal that you cannot go without a tube sticking out of your 224 
stomach.  Or you can’t go somewhere because you’ve got to go home and do 225 
your bag. 226 
 227 
James (0%) however pre-emptively chose peritoneal dialysis to avoid the permanent 228 
fistula related to haemodialysis:  229 
And I chose ….. to go with the peritoneal dialysis, so that I had it at home 230 
mainly because I didn’t want to have the fistula in the arm for life ….. with the 231 
peritoneal I could lead a normal life. 232 
 233 
Dialysis as a downside was therefore aligned with a poorer quality of life, limited 234 
freedoms affecting how participants lived their lives and challenging “normality”. 235 
However, the risk of a return to dialysis - even following a poor previous experience 236 
– could be felt to be worthwhile if the reward was considered to be great enough. 237 
For example Mark (50%) described his prior experience of being “hooked” up to a 238 
machine for eight or nine hours a night as “horrendous” ….. but it was a risk he was 239 
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willing to take in order to lead “ ….. a life without drugs ….. to be able to be normal”.  240 
As he explained:   241 
you never feel well ever ….. . It affects your social life, your emotional and 242 
personal life, sexual life ….. . Just the thought of it [dialysis] is horrendous. ….. 243 
you can’t go away without this, that and the other.  The spontaneity 244 
disappears from your life essentially. 245 
 246 
Although dialysis was generally viewed as a negative experience, or one to be 247 
tolerated, some participants such as Georgina (35%), although not wishing to return 248 
to dialysis, told us her trips to the hospital for haemodialysis had brought 249 
“enjoyment” through the company of other patients and the excellent nursing care 250 
she received, including “the tea and buttered toast”.  Georgina’s account of the 251 
positive elements of her previous experience of dialysis indicates that one should not 252 
divorce medical procedures from either their social setting or the individuals 253 
circumstances and experiences, nor the effect these have on individuals 254 
conceptualisation of downsides and rewards.   255 
 256 
3.2 Rewards of the risk 257 
Whilst the disturbance of graft equilibrium, possible rejection and return to dialysis 258 
were spoken of as conceivable downsides these were often balanced with the 259 
imagined personal rewards of engaging with the risk.  Firstly there was the reduction 260 
in drug side effects. This was important for Mark (50%) and it was also important for 261 
Tom (25%) who had experienced repeat urine infections, methicillin-resistant 262 
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staphylococcus aureus (MRSA) and septicaemia and stated “I would buy into that  ….. 263 
to move away from that [repeat infections], would increase my quality of life”. 264 
 265 
However most participants did not identify the possibility of fewer side effects, 266 
better graft function or long-term health as having a major influence on the risks 267 
they were willing to take. This raised questions concerning how much transplant 268 
patients are told about immunosuppressant drugs. The standard protocol aims to 269 
ensure that all renal transplant patients are fully informed of the effect of anti-270 
rejection medication prior to transplantation (NHS 2015a). However, on speaking 271 
with participants it was clear that often no further conversations about side effects 272 
took place. The first author discussed this with a leading consultant nephrologist 273 
who raised the dilemma of stressing the negative side effects to patients when at 274 
present there is no alternative to immunosuppressive drugs.  His response was, “We 275 
don’t want to upset the patients”. As medication non-adherence is a major reason 276 
for graft rejection (Butler et al 2004) the situation highlights the trade-off with which 277 
both patients and medical professionals have to contend.   278 
 279 
A noted type of ‘reward’ for taking the risk of biomarker led care was meeting the 280 
emotional desires to respond to the social norms of ‘gift exchange’. Whereas the 281 
personal benefits of reducing immunosuppressant side effects were less common 282 
than we expected it was significant that 15 of the participants described the concept 283 
of “giving back” as a reason to risk biomarker led care. Patients expressed how 284 
“lucky” they felt that they had been given such “an unbelievably precious gift” or a 285 
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“gift of life” and moved from general sentiments, such as “wanting to help”, “doing 286 
my bit”, and “paying back” through to more elaborate explanations:  287 
William (50%). Well it’s just like a debt really.  I just feel, I just …, I owe a debt, 288 
you know.  It’s like when somebody does you a favour. ….. I’d be happy to trial 289 
it [biomarker led care], because like I said to you, I feel I owe something back 290 
to the people that have given me this freedom, this better life that I’ve had. …..  291 
 292 
Social theories of gift giving go back to the anthropologist Marcel Mauss (1954) 293 
whose work focuses on the way in which collective exchange practices create 294 
relationships and build social solidarity. However, examining the complexity of 295 
contemporary social gift practice Elder-Vass (2015) debates this ‘exchangist’ 296 
paradigm and argues that a vast amount of giving is not based on exchange but 297 
involves ‘many different kinds of giving, with radically different social and political 298 
implications’ (ibid:15).  Classifying gifting into different forms he expounds on two. 299 
The first is ‘positional giving’ which is examined through the case of giving in families 300 
and similar intimate relationships. Elder-Vass describes this form of giving as 301 
fundamental to family life and it can be seen in the gifting of a kidney within close 302 
relationships. The second form is giving ‘free gifts to strangers’ (ibid:11). This we 303 
argue includes the anonymous donation of living and cadaveric kidneys and the 304 
willingness to be involved in clinical research from which one may not benefit.  In 305 
relation to our study the giving of free gifts to strangers is of particular interest in 306 
two ways. Firstly having received an anonymously donated kidney many of our 307 
participants expressed a desire to reciprocate in some form. When this was in the 308 
nature of agreeing to participate in clinical research our participants often expressed 309 
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this as being for the “benefit of future kidney transplant patients” and not 310 
necessarily themselves. As Lorna (1%) explained:   311 
The night I came in for my transplant, someone came to me and they said, 312 
‘Would you be interested in any research? ….. [I said] ‘Yes, I would.’  You know, 313 
and give back ….. And I was very pleased to – I felt as if I wanted to give 314 
something as what I was getting. 315 
 316 
The question of ‘why’ our participants wished to reciprocate when the gift of a 317 
kidney had essentially been made to a ‘stranger’ raises the notion of  ‘altruism’.  318 
Whether a person is ‘straightforwardly’ altruistic or feels that they, or possibly 319 
somebody close to them, may benefit from the altruistic act renders the concept 320 
complicated. In this case gaining benefit from the ‘altruistic’ act of taking a high risk 321 
with biomarker led care runs counter to the narrative of ‘giving back’ and brings in 322 
the notion of self-interest that has been argued tends to devalue the act of altruism 323 
(Nelkin 1998:36).  However, there is also the notion that in our participants’ case 324 
being willing to take a high risk is based on a form of ‘interlocking obligations’ where 325 
a refusal to give - or in this case take a risk with biomarker led care - ‘is to reject the 326 
bonds of alliance and commonality’ (Douglas 1997:13).  In this manner altruism may 327 
be seen as a calculated notion of potential benefits; an awareness of the inter-328 
dependence of the system of research and medical advancement and the social 329 
responsibility of the role of  ‘kidney transplant patient’.   Hyland (2009) points out 330 
that the fact that ‘reciprocation’ takes place over time – which requires the parties to 331 
cultivate a relationship - distinguishes the gift from the mere exchange which is 332 
reciprocated immediately and thus does not require, nor encourage, a continuing 333 
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bond between the giver and the recipient.  Refusal to reciprocate a gift is equivalent 334 
to the denial of the relationship.  In the case we are examining this seems very 335 
plausible in terms of the close relationship that patients have with the hospital and 336 
staff.  From the kidney transplant patient’s position the mandatory quality of the 337 
counter-gift is just as integral to the nature of the gift as its unilateral quality.  338 
Consequently a person who has received a kidney feels the urge to restore the 339 
balance to the extent that their self-esteem may rest on a successful reciprocation.  340 
Alan (50%) framed his desire in terms of “benefitting others” saying he would be 341 
prepared to “go down to fifty-fifty ….. because if it killed me, the benefits would be 342 
there for others”: 343 
 344 
The emotional tension between the pull to be involved in research and the wish not 345 
to risk a graft is however noticeable in participant’s language:  As Graham (50%) 346 
explained: 347 
….. there’s my desire to learn ….. versus the desire to have as long a 348 
relationship with my partner as I can, and obviously family …..  And that’s, the 349 
tension.  ….. one, I want to help, yes I would dearly love to help … but on the 350 
other hand, if it means me losing years, you know, I’d have to think about 351 
that very carefully.  So that’s what that represents.  You can’t quantify it.  I’m 352 
feeling it.  That’s what I’m feeling. 353 
 354 
Graham’s explanation demonstrates a difficulty in articulating his emotional struggle 355 
between a strong social desire to “help” and an equally strong desire to maximise his 356 
life expectancy. For some however the tension between social integration and 357 
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personal risk was resolved by suggesting any adverse effect would be responded to 358 
rapidly, as Jenny (10%) explained: 359 
I think because we were prepared to go through this, then we should get a bit 360 
of an easier ride back to the top [of the transplant waiting list] ….. I’d be 361 
happier to give myself more freely with a backup plan. ….. I think if they can 362 
say, ‘Right it’s 90%, let’s go for it, and we’ll put you back at the top of the list,’ 363 
then I’d be absolutely fine.  364 
 365 
The notion of ‘giving back’ within the data was therefore found to be complex with 366 
gestures potentially disproportionate to the physical risk of biomarker led care. 367 
Often participants revealed the internal negotiation of anticipated downsides and 368 
rewards. ‘Giving-back’ was hence emotionally charged, often linked to feelings of 369 
responsibility and ‘doing the right thing’ and formed part of an assemblage of 370 
considerations that collectively configured the level of risk a patient was prepared to 371 
take.   372 
 373 
3.3 The notion of ‘trust’  374 
Zinn (2008) describes trust as relying on experienced-based and tacit knowledge, 375 
which in turn is influenced by personal context and feelings or beliefs, producing a 376 
multi-layered concept. In the contemporary world, with its rising complexity, he 377 
views trust as increasingly required, including trust in experts with appropriate 378 
knowledge and skills (ibid:442).  Certainly our data pointed to the prominence of 379 
concepts of ‘trust’, ‘belief’ and ‘faith’, reflecting Zinn’s views that these notions are 380 
relied upon when clear evidence is unavailable.  For example, a deeply emotional 381 
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relationship with a particular consultant led William (50%) to speak of “complete 382 
faith”, “100% faith” in his hospital and medical team, “trust(ing) them implicitly”: 383 
X [name of consultant] is like a godsend in my life. He’s a god. He’d be there 384 
[on the ward] at half past seven at night on a Saturday and he’d just stroke 385 
your leg as if to say, ‘You’re going to be alright.’   Excuse me [Emotional] 386 
 387 
Other participants used similar terminology. For example Alice (25%) described 388 
Zinn’s notion of trust, combined with personal experience in terms of knowledge of 389 
medical advancement: 390 
Because I have absolute faith in the fact that you are being supervised and 391 
because of the care ….. the medical care has been phenomenal. I just trust 392 
them and the way things are moving [medical advancement] they will just 393 
catch stuff, the medical teams and the surgical teams, I do just trust them.  I 394 
have a very high level of trust. 395 
However our data indicated that faith and trust in a medical team did not necessarily 396 
translate into a willingness to take a higher level of risk.  James at 0% stated: 397 
I do value what they say ….. I’ve always really trusted them up here.  They’ve 398 
looked after me really well.  And I will often prefer to get their opinion on 399 
anything, not just my kidney problems, rather than seeing my GP or, you 400 
know, any other specialist.  401 
 402 
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This however may reflect the importance of other factors in James’ life including a 403 
desire to keep physically active and play sport and indeed he questions his own 404 
perspective: 405 
I play golf, football, cycling.  I’ve played eleven months with a kidney 406 
peritoneal dialysis tube.  So I take risks in that way. …. But, yes, that’s quite a 407 
weird one for me to think of, to be honest, because why don’t I [risk 408 
biomarker led care] in that respect if I do play football with a peritoneal 409 
dialysis tube out of my stomach?   410 
 411 
Paul (0%) with a young family to provide for was also not prepared to take any risk 412 
with biomarker led care and echoed the conflict: 413 
If they tell me it’s black and white, it’s black and white, to a certain extent. ….. 414 
I think they’re brilliant, absolutely brilliant. As I said, they’re like family.  415 
Paul’s phrase “to a certain extent” indicates the tension and internal negotiation that 416 
runs through the process of decision-making where risk is concerned.  With little 417 
scientific knowledge available to aid in the decision whether to risk biomarker led 418 
care our participants can be seen to evoke what Zinn (2008) terms the  ‘in-between’ 419 
strategies of trust and emotion in balancing the level of risk they are prepared to 420 
take.  Zinn argues that these strategies, including intuition, complement and 421 
overcome some of the limitations of calculative forms of risk management, 422 
facilitating effective control over the future and echoing Beck’s (1992) argument that 423 
we now look to the ‘estimability’ of risk and that we use ‘beliefs, behaviours and 424 
everyday life’ in our decision-making (Tulloch & Lupton 2003).  425 
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 426 
6. Familial Perception 427 
Mason (2004) argues that a misreading of personal narrative as an individualistic 428 
discursive form has fuelled the hold of the concept of individualism; a concept that 429 
permeates the medical world.  This should be borne in mind when considering the 430 
manner in which families collectively consider the nature of innovative treatments 431 
and in our study was demonstrated by descriptions of patients negotiating risk-432 
taking with their family. Robert (10%) having decided upon his level of risk told us “I 433 
would take a much higher risk, but my wife would kill me!” and Luke (0%) said “I 434 
couldn’t possibly say what risk I would take until I’ve discussed it with my wife and 435 
the family”.   Many participants spoke about discussing any ‘risky’ treatments with 436 
family prior to making a decision. This supports the notion of ‘family ethics’ (Verkerk 437 
et al 2014) and highlights that responsibilities must be negotiated against the 438 
backdrop of family relationships, and treatment decisions made in the light of those 439 
negotiated responsibilities.  It also raises the moral problem of whether the 440 
structure of contemporary medicine, including participation in clinical research, 441 
takes into account the demands it makes on families and how these demands have 442 
the potential to further embed patterns of social behaviour, conceivably injustices. 443 
By treating patients as individuals we ignore harms incurred by family members and 444 
may as a consequence damage relationships (Hardwig 1990).    445 
We had envisaged that familial negotiation would be higher in the case of a living 446 
donation from a family member or friend. However, this was not evident in our data. 447 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20
For example although Oliver (50%) and his mother had become “closer” since her 448 
donation this had not translated into a low level of risk taking:  449 
Pam: ….. it would be obviously his decision.  I mean he’s saying that he would 450 
be more willing to take risks. I think I would be a little bit more reserved than 451 
that. 452 
It would appear therefore that it may not be the origin of the graft per se that leads 453 
to familial negotiation but for some the necessity to discuss risk within relationships. 454 
Luke whose wife donated a kidney to him 8 years ago explained: 455 
Luke (0%): I know it’s my body and all that, but it doesn’t work like that. ….. 456 
we’ve been married now over thirty years, it just doesn’t work like that.  457 
We’re a team and I would never agree to something if she wasn’t in 458 
agreement as well.   459 
 460 
Luke’s comments echo our findings that regardless of whether participants received 461 
a donated kidney from a known source or a cadaveric transplant there is still a 462 
strong drive to discuss the situation with family. This was further illustrated by 463 
William (50%) 464 
 465 
Put my name down first! How do you find out if it’s accurate?  You can’t keep 466 
doing them on rats and mice, can you?  You need somebody to be able to say, 467 
‘Do you know what, I’ll give that a go.’  Yes - my wife might not agree with 468 
that point of view …. I’m the one with the transplant and she’s not, but she’s 469 
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the one who could be left with the children …... We’d talk about it and 470 
ultimately it would be mine and my wife’s decision. 471 
 472 
Jane, Alan’s wife, who would be cautious of anything less than 100% test accuracy, 473 
shares the notion that decisions should be discussed with family:   474 
 I’m more selfish. ….. this is where the research hasn’t been done, on the 475 
impact on families. ….. Alan comes from that point of view – ‘Well I’ve had so 476 
much surgery, it would probably be quite quick, I’m never going to know, I’m 477 
not going to suffer.’  But I’ve been at home with the kids on my own, done the 478 
emotional journey ….. been told, ‘We don’t know if he’s going to pull 479 
through,’ and it was really hard.  480 
 481 
Despite the patient being treated by the medical profession as an individual, our 482 
findings indicate that decision-making where risk is concerned is often a negotiated 483 
affair, predominately with family members being more risk averse and causing the 484 
patient’s judgement to be adjusted in favour of less risky behaviour.  485 
 486 
4. Discussion 487 
The introduction of innovative therapies that carry risks but also offer the potential 488 
of long-term medical benefit raises questions of what patients take into account 489 
when making treatment choices. Our interviews with kidney transplant patients 490 
provide empirical evidence in support of Lupton’s notion of the ‘emotion-risk 491 
assemblage’ where decisions are configured through an accumulation of 492 
considerations that are interwoven by emotional affect. Regardless of whether a 493 
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participant chose to opt for a low or high level of risk it is apparent that the decision 494 
was shaped through analysis of their social and medical situation and their feelings, 495 
with risk being what Lupton described as the enactment of  ‘feelings’ and ‘analysis’ 496 
simultaneously (Lupton 2013:641).  497 
 498 
With graft rejection being a major consideration for kidney transplant patients it was 499 
understandable that many patients chose to continue with their current 500 
immunosuppressant treatment. This was based on more than analytical decisions 501 
with patients “feeling” that their graft was “settled”, “comfortable” or “in a nice 502 
routine”, echoing the ‘gut feeling’ that Lupton speaks of (Lupton 2013:635). 503 
Considering that one of the downsides to rejection may possibly be a return to 504 
dialysis it is further reasonable to argue that the emotion of experience played a role 505 
in patient’s decisions.  506 
 507 
For some people these emotional and practical considerations appeared to have a 508 
strong influence on their risk preference, leading them to opt for the “status quo”. 509 
However a number of patients were prepared to take a higher risk drawn by even 510 
stronger feelings or concerns.  For a few it was a reduction in symptom burden and 511 
the effect this had on their life. However the small number considering issues of 512 
symptom burden and the adverse effects of immunosuppressive drugs may have 513 
been influenced by a lack of in-depth knowledge of the drugs significant adverse 514 
effects.  In addition the study was restricted to patients with ‘stable’ kidney function 515 
whereas patients with unstable function and a heavier symptom burden may have 516 
perceived greater medical gain and been prepared to take a higher risk.  517 
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 518 
Whereas risk-taking has been linked to personality type (McDaniel & Zuckermann 519 
2003) our data point to participants being prepared to take high risks in some areas 520 
of their lives, such as voluntary risk associated with sport, whilst taking a low risk 521 
with biomarker led care, reflecting that the social context of decisions about, and 522 
calculations of, risk are more persuasive. This concurs with Lupton’s perspective on 523 
experiences that involve voluntary risk-taking, such as drug taking and participating 524 
in ‘extreme sports’, where risk-taking is not the product of ignorance or irrationality, 525 
but taken without coercion in the full acknowledgement that risks are being 526 
confronted for reasons of self-improvement, emotional engagement or control 527 
(Lupton & Tulloch 2010).  Supporting this Stephen Lyng (2012) identifies how 528 
voluntary risk-taking produces heightened embodied sensations and emotions thus 529 
further demonstrating the complexities of the production and management of 530 
emotion in risk-taking.  531 
 532 
Considering the prolonged relationship that kidney transplant patients have with 533 
their medical personnel it was understandable that ‘trust’ had a strong influence on 534 
attitudes and behaviours. According to Japp (2000) trust is necessary to generate a 535 
readiness for risk taking (Zinn 2006).  In considering this we need to think carefully 536 
about the reification of the patient that occurs through the process of trust. For 537 
Taussig (1980) physical things, such as the therapies and the ‘technology of healing’ 538 
should not be considered as ‘things-in-themselves’ but also as signs and symbols of 539 
social relations that are disguised as natural things concealing their roots in human 540 
relationships. In Taussig’s opinion by denying these human relations we reproduce a 541 
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political ideology in the guise of a science of (apparently) ‘real things’. In essence 542 
Taussig is pointing to the social relations embedded in disease, and their therapies, 543 
and highlighting the synthesis of the moral, social and physical presentations. 544 
According to Taussig in modern clinical practice and medical culture this function is 545 
camouflaged, concealed by the aura of benevolence and to openly discuss that 546 
which is camouflaged would be to undermine the stability of the present clinical 547 
practice and to question the presently accepted relationship between clinician and 548 
patient.  By doing so we would undermine a stable reality that cannot be denied as 549 
long as professional expertise bears down, as long as authorship is ‘denied’ and 550 
reciprocity makes its presence felt (Taussig 1990:5).  Taussig’s argument therefore 551 
brings into question the value of trust when intent is camouflaged.  We did however 552 
note that trust does not necessarily lead to action, it could be voiced but did not 553 
necessarily translate into a high-risk level. This indicated that feelings of trust and 554 
faith may not preclude stronger emotions or rationales from shaping decisions.  555 
 556 
The social space of kidney transplantation influences not only trust but also emotion 557 
and the desire to ‘give back’, to ‘reciprocate’. In hospital renal clinics where 558 
conversations with medical professionals and indeed other patients focus on 559 
creatinine levels, drug adherence and other medically induced phenomena 560 
enrolments in clinical trials take place.  One participant described the collective 561 
experience as requiring her to be the “good kidney patient”.  This we argue 562 
incorporates the notion of the patient as one who although aware of health risks - 563 
for example adhering to medication regimes) - is one who is prepared to take risks to 564 
be involved in medical research and one who also appreciates they are the recipient 565 
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of a ‘gift’ which as (Mauss 1954) describes carries its obligations to reciprocate. 566 
These notions are important for as Lupton (2013) argues when patients weigh up 567 
risks, or decide to take a risk, they are making assessments of the social meaning of 568 
the phenomena, making sense of the situation and the risk.  This takes into account 569 
that although the risk may be material it is always interpreted via a social or cultural 570 
lens reflecting amongst other things moral judgements within the particular 571 
historical, social, cultural and political context (Lupton 2013b:638). Regardless of risk 572 
levels many participants made reference to the obligation they felt to reciprocate in 573 
some manner for the ‘gift’ they had been given.  For some this went hand-in-hand 574 
with a risk level of 50% raising questions concerning the central place of exchange 575 
and co-operation in society and the role this plays in kidney patients agreeing to 576 
participate in medical research. If one considers ‘gift exchange’ as a social fact then 577 
Durkheim’s argument (1982) is of great relevance, e.g. that the manner of acting, 578 
thinking and feeling that constitutes the social fact (in our case ‘gift exchange’) is 579 
invested with a coercive power by virtue of which it exercises control over the 580 
individual.  This line of argument may explain the almost sacrificial attitude of some 581 
participants and alludes to the way that emotional appeal cannot be divorced from 582 
decision-making, despite medicines focus on rational scientific thought. It also raises 583 
questions concerning the loss of dignity if one is unable to meet the obligation of 584 
reciprocity and how patients may feel this keenly during patient-doctor encounters 585 
or amongst fellow transplant patients and donors.  586 
 587 
Our participants were also aware that treatments for renal failure have improved 588 
because of the willingness of patients to take a risk with new and novel approaches 589 
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and that they themselves might benefit from current research. Coupled with this is 590 
the value reciprocation may have in obtaining resources needed for future life and 591 
the maintaining of social bonds within the clinic. For example we need to understand 592 
how patients perceive the relationship between research studies and organ 593 
allocation and how this affects their risk judgement.  This is of particular relevance to 594 
kidney transplantation where organs fail and it is not unheard of for patients to 595 
require up to three grafts. 596 
 597 
Lupton describes risk judgements as shared and collective rather than located within 598 
the individual (Lupton 2013:644). Similarly our findings reflect the affect that ‘others’ 599 
perspectives have on the assemblage. These include health professionals together 600 
with the influence of familial opinion, with risk levels often mediated to take into 601 
account family feelings and responsibilities.  602 
 603 
5. Conclusion 604 
Our interviews with transplant patients support the notion that emotion is not part 605 
of a linear process preceding and separate to reason but intertwined with the 606 
understanding and perception of risk. Acknowledging the shaping of risk-taking in 607 
this way helps to appreciate the interplay that occurs between different factors that 608 
patients take into account when making risk assessments. It also challenges the 609 
perception of risk-taking by patients as based purely upon a rational weighing of 610 
medical benefit, for example the reduction of symptoms or improved long-term 611 
health. By so doing the study raises important questions concerning the influence 612 
that emotion, social structures and concepts have on the level of risk a patient may 613 
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be prepared to take when invited to enrol in clinical trials.  It also opens up the 614 
possibility that patient choice is based on influences that may not accord with the 615 
framework and intention of medical professionals and medical research. Although 616 
Lupton reminds us that expert judgement is neither free of emotional involvement, 617 
and science itself is inevitably an emotional enterprise, there is still the need to 618 
consider the ways in which research within the arena of clinical medicine may 619 
produce a tension arising from a collision with patients and familial frameworks.  620 
 621 
The field of kidney transplantation is to a certain extent peculiar in the medical 622 
domain with notions of repeated transplantation and requirements for organ 623 
donation.  As a consequence the individual factors that influenced our participants' 624 
decision-making may not be applicable across medicine. However we argue that the 625 
notion of the ‘emotion-risk assemblage’ is and provides a tool to enable discussion 626 
and explanation of medical risk-taking particularly in the field of clinical trials. Our 627 
research highlights the need when health choices are being made to couple 628 
information provision with counselling for patients when health choices are being 629 
made to help patients chose an option that best accommodates their physical health 630 
and personal interpretation of the risk they may be taking. This would provide a 631 
conduit between the patient’s ‘emotion-risk assemblage’ and the intended scientific 632 
rationale of the medical research and ensure a space for patient and medical 633 
professionals to unpack and discuss the best available option. 634 
 635 
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    PARTICIPANTS  
 
TABLE 1                   
Pseudonym Age Cadaveric Living Location Transplant(s)  Partner Children Dialysis Risk Level 
Robert 42  
  South Yorks (SY) 2009 Yes One, 9 18 months 10% 
Lucy 35  
  South-East (SE) 2000 No No 7 years  20% 
Colin 63  
  SE 2007 No Two, 18+ 12 months 40% 
Miranda 59    SY 1996 Yes No 6 months 0% 
Jessica 28    SE 1997 Yes Pregnant 12 months 2% 
James 27  
  SE 2000 Yes No 11 months 0% 
Imelda 50    SE 2006 No No 2 years 20% 
Lorna 60    SE 2002 No Two, 18+ 1.25 years 1% 
Graham 68    SE 2001 Yes Two, 18+ <year 50% 
Sanji 56    SE 1999 Yes Two, 18+ <year 0% 
Georgina 64  
  SE 1990 No One, 18+ No 35% 
Betty 55    SE 1982 & 1985 Yes Two 4.5 years 3% 
Alan 50    SE 1997 Yes Two, 18+ No 50% 
Jenny 41    SE 2004 Yes One, 9 9 months 10% 
Luke 52  
  SE 2005 Yes Three, 18 + 12 months 0% 
Kate 58    SE 1988 Yes Stepson, 18+ 9 years 5% 
Oliver 34  
  SE 2003 No No 12 months 50% 
Jack 61    SE 1970 & 1998 Yes No 26 years 0% 
William 54    SE 2000 Yes Two, 18+ <year 50% 
Mark 51    SE 1999 No No <year 50% 
Dawn 48  
  SE 2004 Yes No 2 years 0% 
Paul 44  
  SE 2008 Yes Two, 6 and 9 No 0% 
Alice 42    SE 2007 Yes No No 25% 
Tom 37    SE 2006 No No 8 years 25% 
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Understanding kidney transplant patients’ treatment choices: the 
interaction of emotion with medical and social influences on risk 
preferences  
 
 
 
Highlights 
 
Biomarker tests of graft tolerance cannot be 100% accurate, risking kidney rejection 
Dialysis concerns, familial views, trust & ‘gift exchange’ shaped decision-making  
These experiences & circumstances were intertwined with emotional influences 
Patients’ decision-making supports the notion of Lupton’s ‘emotion-risk assemblage’  
This assemblage highlights a tension with medical frameworks and medical research 
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